In general, HR+/HER2− patients mostly presented with T1 tumours (9/14; 64%) and TNBC patients (27/51; 53%) as well as HR−/HER2+ patients (5/10; 50%) with T2 tumours, respectively. The gene discussed is HR; the disease is neoplasm.